Exhibit 99.1 Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights • Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells • Announced initial clinical data from our Phase 2 study (COVALENT-112) in type 1 d ...